The Health Policy Partnership

Tweet this page
Registration as it was on 07 Dec 2020
How to read and use this data card.
Download this datacard


Lobbying Costs


Financial year: Jan 2019 - Dec 2019

Lobbyists (Full time equivalent)

1.5 Fte (6)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    The Health Policy Partnership   (HPP)

    EU Transparency Register

    223430420230-66 First registered on 08 Jan 2016

    Goals / Remit

    We are a specialist health policy consultancy. We create innovative policy initiatives and powerful evidence–based communications for organisations across the health spectrum. We provide a unique, seamless approach to help resolve the most complex issues facing our health care systems. We do this through rigorous research and expert synthesis of evidence, inter-sectoral collaboration, and powerful communications that act as the starting point for meaningful changes in policy and practice.

    Main EU files targeted

    HPP is a member of the The EU Health Policy Platform (representing the HFPN). See:


    Head Office
    The Health Policy Partnership
    68-69 St Martin's Lane
    London WC2N 4JS
  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    Time provided above relates to HPP staff time dedicated to any formal engagement with MEPs, EU officials, or where there is policy activity directly involving or targeting EU institutions - i.e. it excludes general health policy activities where other audiences are our primary targets (e.g. national policy makers, academic experts, clinicians, health providers etc), and global activities.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    I - Professional consultancies/law firms/self-employed consultants


    Professional consultancies

  • Networking


    Heart Failure Policy Network -
    (provide secretariat and lead project)

    Knowledge partner for the Coalition to Eradicate Viral Hepatitis from Asia Pacific (

    Member organisations

    Please see

  • Financial Data

    Closed financial year

    Jan 2019 - Dec 2019

    Lobbying costs for closed financial year


    Other financial info

    None declared

    Declared lobby clients

    Client Name Amount
    Advanced Accelerator Applications 200,000€ - 299,999€
    ASTRA ZENECA 50,000€ - 99,999€
    Curium 10,000€ - 24,999€
    Novartis AG 25,000€ - 49,999€
    Vifor Pharma 25,000€ - 49,999€
  • EU Structures

    Groups (European Commission)


    Groups (European Parliament)


    Communication activities

    HPP acts as Secretariat for the HF Policy Network, a multidisciplinary group of politicians from across Europe working with patients, health professionals and other stakeholders to lead significant policy changes that may improve the lives of people with heart failure (HF).

    The HFPN has ongoing relationships with several MEPs who donate their time for free to support (and act as Members of) the HFPN. In 2020, HFPN launched the "Heart failure policy and practice in Europe" project. The project aims to support advocates with a clear outline of policy issues and best practice in heart failure across 11 European countries. A virtual launch, supported by Billy Kelleher MEP, was on the 9 December 2020.

    HPP established a multi-stakeholder steering committee comprising patient advocates and experts in oncology and nuclear medicine from across Europe, to develop a policy report to raise awareness of radioligand therapy as an innovative component of cancer care. Through desk research and interviews with additional stakeholders, the report was drafted to reflect the consensus of the steering committee.

    Alongside the main report, HPP created an animated video on radioligand therapy, to explain this complex process to a wider audience. We also created a two-page report summary featuring a top-line explanation of radioligand therapy and a distillation of the report’s recommended actions to overcome barriers to integration of radioligand therapy in clinical cancer care.

    The report and other outputs were launched during an event at the European Parliament in Brussels on Wednesday 22 January 2020, which was co-hosted by Tanja Fajon MEP and Ewa Kopacz MEP. This was the first European-level policy meeting on radioligand therapy.

    Other activities

    None declared

  • Meetings


    1 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: All information below comes from European Commission web pages.

    • Date 25 Oct 2023 Location Brussels, Belgium
      Subject Role of the EU in promoting heart health
      Cabinet Cabinet of Commissioner Mairead Mcguinness
      Portfolio Financial services, financial stability and Capital Markets Union
      • Katherine Power (Cabinet member)
Download this datacard